Q4 EPS Estimates for 908 Devices Reduced by Leerink Partnrs

908 Devices Inc. (NASDAQ:MASS) – Investment analysts at Leerink Partnrs reduced their Q4 2025 earnings per share estimates for 908 Devices in a report released on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the company will earn ($0.25) per share for the quarter, down from their prior estimate of ($0.24). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for 908 Devices’ current full-year earnings is ($1.99) per share. Leerink Partnrs also issued estimates for 908 Devices’ FY2026 earnings at ($1.10) EPS.

Several other equities analysts have also recently commented on MASS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 908 Devices in a research report on Saturday, January 18th. Stifel Nicolaus decreased their target price on 908 Devices from $17.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Leerink Partners reiterated a “market perform” rating and issued a $4.00 price target (down from $12.00) on shares of 908 Devices in a report on Wednesday, November 13th. Finally, Stephens restated an “overweight” rating and set a $6.00 price objective on shares of 908 Devices in a research note on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.33.

908 Devices Price Performance

NASDAQ MASS opened at $2.74 on Thursday. The company’s fifty day moving average price is $2.36 and its two-hundred day moving average price is $3.46. The company has a market capitalization of $95.37 million, a price-to-earnings ratio of -1.55 and a beta of 0.96. 908 Devices has a 12 month low of $1.81 and a 12 month high of $8.50.

Institutional Investors Weigh In On 908 Devices

Hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. grew its stake in 908 Devices by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company’s stock valued at $765,000 after acquiring an additional 28,015 shares in the last quarter. Geode Capital Management LLC increased its stake in 908 Devices by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 567,788 shares of the company’s stock valued at $1,970,000 after buying an additional 6,634 shares during the period. Millennium Management LLC boosted its stake in shares of 908 Devices by 35.5% during the 2nd quarter. Millennium Management LLC now owns 618,310 shares of the company’s stock valued at $3,184,000 after buying an additional 161,922 shares during the period. State Street Corp increased its stake in shares of 908 Devices by 1.2% in the third quarter. State Street Corp now owns 479,044 shares of the company’s stock worth $1,662,000 after acquiring an additional 5,704 shares during the last quarter. Finally, Barclays PLC boosted its position in 908 Devices by 452.7% during the third quarter. Barclays PLC now owns 46,214 shares of the company’s stock valued at $160,000 after purchasing an additional 37,853 shares during the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.